Matthew J. Pfeffer is a finance expert with a solid background in managing financial operations in the biotech sector. He earned his bachelor’s degree from UC Berkeley and built a career with over 25 years of experience. Before becoming CEO...

Matthew J. Pfeffer is a finance expert with a solid background in managing financial operations in the biotech sector. He earned his bachelor’s degree from UC Berkeley and built a career with over 25 years of experience. Before becoming CEO of MannKind Corporation in 2016, he was Chief Financial Officer at VaxGen and Cell Genesys. His leadership at MannKind is marked by a focus on strategic financial management to support the company’s growth. Interestingly, Pfeffer’s compensation has fluctuated significantly during his time at MannKind, with total pay reaching over $3.2 million in 2016 but dropping to around $746,000 in 2017 where he also received no bonus. His use of stock options has seen impressive jumps, most recently selling insider shares worth between $106K to $503K monthly from 2019 through 2024. Pfeffer's approach blends financial discipline and an understanding of biotechnology's complexities, illustrating how crucial leadership is in navigating the biotech industry's challenges and opportunities.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Mannkind CEOs

M

Matthew J. Pfeffer

Ex-CEO of Mannkind

Education

Bachelor's degree from University of California, Berkeley

Field of Expertise

Finance & Banking - Finance

Sector of Economy

Healthcare

Born

January 1, 1960 - 65 years ago

CEO of Mannkind for

1 year 4 months (Jan 2016 - May 2017)

Previous Experience

CFO of VaxGen, Inc.

Rivals

Competitors/colleagues of Matthew J. Pfeffer

Holdings

See how much did Matthew J. Pfeffer make over time.

Matthew J. Pfeffer’s insider trading activity shows substantial fluctuations over the years. In late 2019 and early 2020, his monthly sales ranged from $90K to a high of $278K in January 2021. Following this peak, he consistently sold shares, hitting...

Matthew J. Pfeffer’s insider trading activity shows substantial fluctuations over the years. In late 2019 and early 2020, his monthly sales ranged from $90K to a high of $278K in January 2021. Following this peak, he consistently sold shares, hitting a peak of $503K in September 2024. Despite reductions in his role's short-term compensation, Pfeffer has maintained significant financial stakes in the company, reflecting confidence in ManKind's long-term prospects. His financial moves reveal an understanding of market conditions and timing, as seen in over 40 separate trades from 2019 to 2024, demonstrating a keen insight into stock performance and potential growth areas.

Loading...

Total Stock Sold

$2.89M

MNKD

$2.89M

13,260 MNKD shares

What if they kept their stock?

If Matthew J. Pfeffer didn't sell their stock, today they would have:
Extra MNKD13,260 shares worth $29.30K.
This is -98.99% and $2.86M less than what they got when they sold the stock.

Charitable Transactions

MNKD

220 shares

MNKD

Recent Charitable Transactions

MNKD

1,100 shares

MNKD

Dec 31, 2014

Charity

Insider Trading

See recent insider trades of Matthew J. Pfeffer.

MNKD

$2.46K

MNKD at $1.23/share

Jun 30, 2017

Purchase

MNKD

$2.45K

MNKD at $0.54/share

Jan 3, 2017

Purchase

MNKD

$24.65K

MNKD at $0.99/share

Aug 15, 2016

Purchase

MNKD

16,100 shares

MNKD

Aug 27, 2015

Received

MNKD

15,000 shares

MNKD

Feb 23, 2015

Received

MNKD

1,100 shares

MNKD

Dec 31, 2014

Charity

MNKD

229,700 shares

MNKD

Aug 11, 2014

Received

MNKD

$208.77K

MNKD at $10.44/share

Jul 1, 2014

Sale

MNKD

$2.33K

MNKD at $4.42/share

Jun 30, 2014

Purchase

MNKD

229,000 shares

MNKD

Oct 14, 2013

Received

Compensation History

See how much did Matthew J. Pfeffer make over time.

Matthew J. Pfeffer's compensation as CEO of MannKind Corporation saw notable changes during his tenure. In 2016, he received over $3.2 million in total compensation, including salary, bonuses, and vested stocks. This reflected his pivotal role during a crucial period for the company. By 2017, his total compensation dropped to about $746,000, with no bonus awarded. This drop illustrates the volatility that can happen in executive compensation, especially in the biotech sector, where success may depend heavily on the company’s project performance and market conditions. Despite these fluctuations, Pfeffer's long-term equity retention strategy has kept him invested in the company's future, suggesting a strong belief in its potential.

Year

2017

Total Compensation

$605.24K

Salary

$575.43K

Board Justification

The compensation philosophy is designed to attract and retain the individuals needed to support the business strategy and to allow the company to compete effectively with pharmaceutical and biotechnology companies.

Bonus

$0.00

Board Justification

The CEO was eligible to receive an annual bonus for 2017 pursuant to the standard bonus compensation structure applicable to the Company’s executive officers, but did not receive a bonus in 2017.

Other

$27.23K

Board Justification

Other compensation includes auto allowance, contributions under the 401(k) plan, medical benefits, and other taxable income.

Restricted Stock

$2.59K(1.74K RSU)

Board Justification

The stock that vested in 2017 was part of restricted stock awards, which vest annually over a four-year period.

Performance Metrics

The performance metrics for determining the compensation included achieving corporate objectives related to operational goals.

Other Mannkind CEOs

Here are other CEOs of Mannkind

Hakan S. Edstrom

Ex-CEO of Mannkind

January 2015 - November 2015

Michael E. Castagna

CEO of Mannkind

May 2017 - Present